Implantable Port Systems Research Articles

Early Results of Totally Implantable Central Venous Access Port Insertion Through a Supraclavicular Approach

Cancer patients usually require repeated venous punctures for chemotherapy or other reasons. Therefore, totally implantable venous access port (TIVAP) systems have been helpful for patients with difficult vascular access. The purpose of this study was to evaluate the safety and feasibility of the totally implantable venous access port (TIVAP) implanted using a supraclavicular approach. After identification of the anatomical landmarks (clavicular head of the sternocleidomastoid muscle) for a supraclavicular approach, the patient was anesthetized with 1% lidocaine. After puncturing the central vein with an 18-G needle, the Seldinger catheterization procedure was performed. Between March 2017 and February 2018, 89 totally implantable venous access ports (TIVAPs) were inserted in 89 consecutive patients (32 men and 57 women) with a mean age of 57.5 years (range, 19–89 years) through a supraclavicular approach. Successful totally implantable venous access port (TIVAP) implantation was achieved in 96.6% (86 of 89) of patients. In 2 patients, port catheter placement failed despite successful vascular puncture because a wire could not be passed after cannulation of the blood vessel. The other case of failed placement was due to development of pneumothorax during vascular puncture. Venous port-related complications such as bleeding, infection, thrombosis, malfunction, or catheter fracture did not occur within 2 postoperative weeks. Totally implantable venous access port (TIVAP) implantation through the supraclavicular approach can be performed safely and feasibly for oncologic patients with difficult central or peripheral venous access.

Clinical case of using of implantable spinal access port system

This paper presents our experience of implantation and operation of the spinal access port system on the example of patient P, 78 years old. The admission diagnosis: malignant neoplasm of pancreas. Surgical treatment is contraindicated due to multiple metastases to the abdominal organs and lymph nodes. On admission to the hospital, the patient complained of persistent abdominal pain [68 points on Visual Analog Scale for Pain (VAS Pain)] was not relieved by the injection of NSAIDs and narcotic analgesics (morphine hydrochloride). We have decided to implant the spinal access port system to the patient aimed at neuraxial analgesia techniques. According to the World Health Organization (WHO), about 3.5 million people every day around the world suffer from cancer-related pain every day. The difficulties associated with the ineffectiveness of traditional pharmacological interventions for pain management lead to search alternative pain management. One of the aims of the paper is to attract the attention of treating doctors, surgeons, anesthesiologists to this technique because since it allows to reduce or relief of pain in this group of patients and improve their quality of life.

SIMULATION TRAINING OF ONCOLOGICAL NURSES IN THE SKILLS OF CARING FOR IMPLANTABLE VENOUS PORT SYSTEMS. EXPERIENCE OF NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY NAMED AFTER N. N. BLOKHIN

The work proves the need for training nurses in the skills of caring for implantable venous port systems using simulation technologies.

445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments

BackgroundColorectal cancer (CRC) patients treated with curative intended surgery undergo 5-FU continuous infusion based chemotherapy using totally implantable central venous port system (TICVPS) in case of high-risk of recurrence. Approximately 30% patients relapse after the completion of therapy, especially within 2 years. Hence, many of high-risk CRC patients keep the TICVPS during 6-24 months after treatment, with regular intervals of TICVPS flushing. The manufacturer recommends monthly flushing for maintain TICVPS, however the interval of flushing lacks scientific evidence. The aim of this study is to investigate whether the extended maintenance intervals is safe and feasible. MethodsA retrospective cohort was conducted in CRC patients who underwent curative intended surgery and perioperative chemotherapy using TICVPS between 2010 and 2017. Patient were enrolled if TICVPS was maintained at least 6 months with 3-month interval flushing using heparin, while patient who were recurred within 1 month, removed TICVPS within 6 months without definitive causes, or violation of flushing interval were excluded. The primary end points were the functional TICVPS maintenance rate. ResultsA total of 214 CRC patients underwent curative intended treatments during the study period. Among them, 6 patients (early recurrence within 1 month) and 54 patients (violation of flushing interval) were excluded, finally 154 patients were analyzed. Mean flushing interval was 98.4 days. At the Dec 2018, 35 patients kept the TICVPS, 92 were planned removal, and 25 were reused the TICVPS, while two patients had to unexpectedly remove due to TICVPS site infection and pain. Thus, the functional TICVPS maintenance rate was 98.8%. 38 patients were relapsed and 30 were treated with intravenous chemotherapy. Among them, 25 patients (83.3%) were reused the existing TICVPS without re-insertion procedure. ConclusionsOur study demonstrated that 3-month interval flushing is safe and feasible in CRC patients. Extended time interval up to 3 months might be considered because it is compatible with CRC surveillance visit schedules and convenient for patients. Legal entity responsible for the studyThe authors. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest.

Locking of venous port systems in breaks between infusion cycles: heparinized or normal saline?

BACKGROUND. For many years, the use of heparinized saline was considered as standard practice for flushing and locking of implantable venous port systems, although this approach is not substantiated. As an alternative to heparin solution, one can use a normal saline. MATERIALS AND METHODS. A literature analysis was carried out, including practical recommendations for the care of port systems, scientific articles and clinical studies on the comparative effectiveness and safety of heparinized and normal saline for locking port systems in adult patients. RESULTS. Long-term use of even low doses of heparin can lead to bleeding and thrombocytopenia, especially in dialysis and cancer patients, which can lead to serious or life-threatening complications. The use of heparin is associated with errors in dosage, the formation of S. aureus biofilms, and incompatibility with other drugs. The results of retrospective and randomized prospective studies indicate that the use of normal saline for locking of port systems is effective and safe and is not associated with an increased risk of complications. CONCLUSIONS. In patients of various profile (with malignant tumors and other pathologies), the use of a normal solution for locking implantable venous ports instead of a heparinized solution is effective and safe. Refusal of heparin eliminates the risks associated with its use, saves time and costs for medical staff and patients.

Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects.

Background 5-Fluorouracil (5-FU) is frequently used for the treatment of gastrointestinal tumors. The pharmacological effect of 5-FU is influenced by genetic polymorphisms as well as differently dosed regimens. Currently, 5-FU is generally administered as a continuous infusion via an implanted port system using a body surface area (BSA)-based dose calculation. In order to optimize treatment, the area under the curve (AUC) can be estimated to allow for individual dose adjustment. A 5-FU AUC range between 20 and 30 [mg×h×L] is recommended. The aim of the current study was to assess if blood for AUC analysis could also be drawn at the side where the port system had been placed. Methods We collected EDTA blood samples of patients receiving infusional 5-FU simultaneously from different sampling points (right/left cubital vein). 5-FU concentrations were measured in a steady-state equilibrium based on nanoparticle immunoassay (My5-FU; Saladax). Results A total of 39 patients took part in this study. About half of the patients did not reach the target 5-FU concentration window (37% were under- and 16% of the patients were overdosed). Calculated median AUC was 23.3 for the right arm (range 5.8-59.4) and a median of 23.4 for the left arm (range 5.3-61.0). AUC values showed no difference between right compared to left arms (p=0.99). Conclusions In all, these results confirm that a high percentage of patients are not treated with 5-FU doses reaching suggested AUC levels of 20-30. The location of venepuncture, however, had no impact on the results of plasma 5-FU concentration.

Evaluation of complications of totally implantable central venous port system insertion

The aim of the present study was to describe the procedure of totally implantable central venous port system (TICVPS) insertion performed at our center and investigate associated complications. The study retrospectively evaluated 827 patients who underwent a single-type TICVPS insertion from January 2013 to July 2015. The length of the procedure, long-term device function, angle (chamber-to-tip) and complications of TICVPS, including infection, skin erosion, occlusion, malposition and thrombosis, were analyzed from the patients' medical records. A total of 843 TICVPS insertions were performed in 827 patients. The TICVPS implantation was successful in all cases (100%). A total of 34 cases (4.0%) with complications were recorded. Complications at the chamber insertion site occurred in 11 patients (1.3%), including 5 infection (0.6%) and 6 erosion cases (0.7%). All patients with chamber insertion site infection were treated by administration of antibiotics and dressing. Of the patients in which chamber insertion site erosion occurred, 2 were subjected to TICVPS removal and reinsertion and 4 were treated with debridement, irrigation and resuture. The most common type of complication was catheter-associated (2.3%; n=19). Among these cases, 7 had catheter-associated infection (0.8%), 8 had catheter migration (1.0%) confirmed by chest radiography, 4 had catheter-associated thrombosis (0.5%) and 2 had chamber malposition (0.3%). The present retrospective study on TICVPS, which used a relatively large cohort, demonstrated a low complication rate (4.0%) compared with that reported in previous studies (5–20%). A well-designed procedure, experienced vascular surgeons, an aseptic operating room environment, ultrasound-guided puncture, a wide angle (chamber-to-tip) and the use of fluoroscopy with contrast agent may reduce the complication rate of TICVPS insertion.

Totally implantable central venous port: analysis of complications and their prevention

To analyze postoperative complications of totally implantable central venous port system (TIPCVP) deployment and develop methods of their prevention. The study involved 43 patients who underwent TIPCVP implantation through right-sided jugular access and 3 patients with migration of the catheter transferred to the Domodedovo Central City Hospital. There were four perioperative and one early postoperative complication. None of the complications was the reason for removal of TIPCVP. Pinch-off syndrome occurred in two patients who were operated in other hospitals and a catheter was inserted through the right subclavian vein. Injury of the carotid artery and pneumothorax can be avoided by ultrasound navigation during internal jugular vein puncture. Catheterization of the internal jugular vein is useful to avoid pinch-off syndrome. Migration of the catheter is successfully cured by endovascular methods.

Safety of administration of bevacizumab within a week from placement of a totally implantable central venous port system.

589 Background: Totally implantable central venous port systems (TICVP) are easy to implant on an in- or outpatient basis and provide reliable, long-lasting central venous access for treatment of intravenous anti-cancer chemotherapy in patients with cancer but it is needed to cut 3cm of patients’ skin at the operation. Bevacizumab is one of the anti vascular endothelial growth factor (ant-VEGF) antibody which is known to improve overall survival in patients with colorectal cancer but have a side effect of delayed wound healing. There are few reports about the safety of administration of bevacizumab in a short period of time from the small surgery such as placement of TICVP. Methods: Patients who were placed TICVP in Department of Gastroenterology of Hokkaido University Hospital from July 2009 to December 2016. We planned to compare the rate of post-operative wound dehiscence (POWD) and surgical site infection (SSI) between patients who administered bevacizumab within a week from placement of TICVP (Group A) and the other patients (Group B). Patients who didn’t receive any chemotherapy after placement of TICVP were excluded. Results: We found 432 patients who implanted TICVP, and excluded 32 patients who didn’t receive any chemotherapy. 50 patients were assigned to Group A and 350 patients were assigned to Group B. Median age in both group were 67.5 in Group A and 65 in Group B. The averages of operation time were 38.7 (+/-19.3) minutes in Group A and 36.4 (+/-19.5) minutes in Group B. Prophylactic antibiotics were given to 27 patients (54%) in Group A and 146 patients (48.7%) in Group B. The rate of POWD was 0.0% (0/50) in Group A vs 1.1% (4/350) in Group B ( p = 0.45 ) , and the rate of SSI was 0.0%(0/50) in Group A vs 1.1% (4/350) in Group B ( p = 0.45 ) . The average of operation time of patients with and without POWD was 56.4 minutes and 36.7 minutes (p = 0.013). Conclusions: In our study, it was found that there is no significant increase of incidence by administration of bevacizumab within a short period from placement of TICVP. The long operation time tends to increase the rate of POWD.

Totally Implantable Central Venous Port Catheters: Radiation Exposure as a Function of Puncture Site and Operator Experience.

Totally implantable central venous port systems provide a safe and effective, long-term means of access for administration of hyperosmolar, local irritant medication, such as chemotherapy, antibiotics and parenteral nutrition. To evaluate the combination of access site and level of experience on fluoroscopy times (FT) and dose area products (DAP) during implantation of port catheters in a large patient population. A total of 1,870 patients (992 women, 878 men; age: 61±13.14 years) were reviewed investigating two groups of junior (≤50 implantations) and senior (>50) radiologists. Senior radiologists required less FT/DAP (0.24 s/57.3 μGy m2 versus 0.43 s/68.2 μGy m2, respectively; p<0.001). Right jugular vein access required the least FT/DAP (0.25 s/56.15 μGy m2) and right-sided implantation lower FT/DAP (right: 0.26 s/56.4 μGy m2, left: 0.40 s/85.10 μGy m2, p<0.001). Due to DAP/FT reductions, the right jugular vein seems to be the most favorable implantation side for port systems. For further dose reduction, residents should be well-trained.

РОЛЬ ИМПЛАНТИРУЕМОЙ ПОРТ СИСТЕМЫ В ЛЕЧЕНИИ ТУБЕРКУЛЁЗА ЛЁГКИХ С МНОЖЕСТВЕННОЙ И ШИРОКОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТЬЮ (ПРЕДВАРИТЕЛЬНЫЕ РЕЗУЛЬТАТЫ)

Objective: To study the role of the implantable port system (IPS) in the treatment of pulmonary tuberculosis with multiple and extensively drug resistance (MDR TB, XDR TB). Methods: Since September 2017, IPS (POLYSITE 4008 ECHO) implanted in seven patients (4 men and 3 women) with MDR and XDR forms of pulmonary tuberculosis in the age of 30 to 60 years. All IPS implanted under the local anesthesia in the operation room. Port system installed with catheterization of the subclavian vein, mainly on the right. All these patients at the time of IPS installation received a short course of chemotherapy with new and before profiled preparations after having passed through a Consultation on drug-resistant tuberculosis. Results: The use of IPS for patients with MDR TB and XDR TB pulmonary tuberculosis demonstrated a high level of commitment to treatment. Only in one case, the infection and suppuration of punction area took place in short-term period. This complication was corrected by secondary surgical treatment and overlay of secondary seams. Conclusion: The preliminary results of the IPS application for seven patients with MDR TB and XDR TB demonstrated high safety and effectiveness of the technique, which allows recommending it, be for further expanded use in the treatment of this patients. Keywords: Tuberculosis treatment, MDR TB, XDR TB, implantable port system.

The experience of patients living with a vascular access device.

British Journal of NursingVol. 26, No. 19 NIVAS Conference ReportsThe experience of patients living with a vascular access deviceLinda J KellyLinda J KellySearch for more papers by this authorLinda J KellyPublished Online:25 Oct 2017https://doi.org/10.12968/bjon.2017.26.19.S36AboutSectionsView articleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareShare onFacebookTwitterLinked InEmail View article References Johansson E, Björkholm M, Björvell H et al.. Totally implantable subcutaneous port system versus central venous catheter placed before induction chemotherapy in patients with acute leukaemia—a randomized study. Support Care Cancer. 2004; 12(2):99–105. https://doi.org/https://doi.org/10.1007/s00520-003-0558-1 Crossref, Medline, Google ScholarRitchie M, Kelly LJ, Moss J, Paul J, Shaw R. Exploring attitudes towards a randomised controlled trial of venous access devices—a nested pre-trial qualitative study. J Vasc Access. 2015; 16(5):407–412. https://doi.org/https://doi.org/10.5301/jva.5000447 Crossref, Medline, Google ScholarSmith JA, Flowers P, Larkin M. Interpretative phenomenological analysis: theory, method and research. London: Sage Publishing; 2009 Google Scholar FiguresReferencesRelatedDetailsCited byA prospective audit evaluating use of urokinase in oncology patients with occluded central venous access devicesKaren Harrold, Annette Martin, Neel Bhuva24 October 2019 | British Journal of Nursing, Vol. 28, No. 19Health professionals' lack of knowledge of central venous access devices: the impact on patientsLinda J Kelly, Austyn Snowden, Ruth Paterson, Karen Campbell26 July 2019 | British Journal of Nursing, Vol. 28, No. 14 26 October 2017Volume 26Issue 19ISSN (print): 0966-0461ISSN (online): 2052-2819 Metrics History Published online 25 October 2017 Published in print 26 October 2017 Information© MA Healthcare LimitedPDF download

A novel paraplegia model in awake behaving macaques.

Lower limb paralysis from spinal cord injury (SCI) or neurological disease carries a poor prognosis for recovery and remains a large societal burden. Neurophysiological and neuroprosthetic research have the potential to improve quality of life for these patients; however, the lack of an ethical and sustainable nonhuman primate model for paraplegia hinders their advancement. Therefore, our multidisciplinary team developed a way to induce temporary paralysis in awake behaving macaques by creating a fully implantable lumbar epidural catheter-subcutaneous port system that enables easy and reliable targeted drug delivery for sensorimotor blockade. During treadmill walking, aliquots of 1.5% lidocaine with 1:200,000 epinephrine were percutaneously injected into the ports of three rhesus macaques while surface electromyography (EMG) recorded muscle activity from their quadriceps and gastrocnemii. Diminution of EMG amplitude, loss of voluntary leg movement, and inability to bear weight were achieved for 60-90 min in each animal, followed by a complete recovery of function. The monkeys remained alert and cooperative during the paralysis trials and continued to take food rewards, and the ports remained functional after several months. This technique will enable recording from the cortex and/or spinal cord in awake behaving nonhuman primates during the onset, maintenance, and resolution of paraplegia for the first time, thus opening the door to answering basic neurophysiological questions about the acute neurological response to spinal cord injury and recovery. It will also negate the need to permanently injure otherwise high-value research animals for certain experimental paradigms aimed at developing and testing neural interface decoding algorithms for patients with lower extremity dysfunction.NEW & NOTEWORTHY A novel implantable lumbar epidural catheter-subcutaneous port system enables targeted drug delivery and induction of temporary paraplegia in awake, behaving nonhuman primates. Three macaques displayed loss of voluntary leg movement for 60-90 min after injection of lidocaine with epinephrine, followed by a full recovery. This technique for the first time will enable ethical live recording from the proximal central nervous system during the acute onset, maintenance, and resolution of paraplegia.

1406 - Management and early complications of totally implantable venous access port systems in 81 children diagnosed with cancer

1406 - Management and early complications of totally implantable venous access port systems in 81 children diagnosed with cancer

The effect of intraumbilical fetal nutrition via a subcutaneously implanted port system on amino acid concentration by severe IUGR human fetuses.

To determine if intrauterine intraumbilical supplementation with amino acids (AA) and glucose can improve neonatal outcome of severe growth restricted human fetuses (IUGR). Prospective pilot study of intrauterine treatment of severe IUGR fetuses [n=14, 27 weeks of gestation (range 23-31)] with cerebroplacental ratio <1, with long-term intraumbilical AA and glucose supplementation (10% of feto-placental blood volume/day) using a perinatal port system alone (n=5) or combined with hyperbaric oxygenation (n=1, HBO) vs. control group (n=8). The duration of continuous intraumbilical AA/glucose supplementation was 11 (6-13) days. Daily intravascular fetal nutrition significantly prolonged the brain sparing to delivery interval by 24 (14-33) days vs. 5.6 (2-12) days in controls. Fetal nutrition reduced blood flow resistance in the placental circulation but did not affect the Doppler profile of cerebral arteries. Higher weight gain of 113.5 (36-539) g was observed following supplementation compared to 33.3 (8-98) g in the control group (P<0.05). In spite of this, fetuses below 28 weeks of gestation did not sufficiently benefit from infused commercial AA. We found a reduced fetal plasma concentration of the essential AA histidine, threonine, lysine and arginine, and non-essential AA taurine, in severe IUGR fetuses in both groups. Long-term supplementation with a commercial AA formula led to a slight, but not significant, reduction of histidine, threonine, lysine, arginine, asparagine and glutamine. However, the concentration of tryptophan and glutamic acid slightly increased. HBO can be combined with AA supplementation via a port system. In one case, the port system was also successfully used for fetal blood transfusion. Intravascular treatment of IUGR with fetal nutrition can prolong pregnancy with severe placental insufficiency and brain sparing for many weeks. However, rather than normalizing AA concentrations, an enhanced AA imbalance was observed in IUGR fetuses following supplementation. These deviations in AA concentrations prevent the recommendation for use of commercial AA solutions for prenatal treatment of extreme preterm IUGR fetuses.

Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients

BackgroundTotally implantable venous access port systems are widely used in oncology, with frequent complications that sometimes necessitate device removal. The aim of this study is to investigate the impact of the time interval between port placement and initiation of chemotherapy and the neutropenia-inducing potential of the chemotherapy administered upon complication-related port removal. Patients and methodsBetween January 2010 and December 2013, 4045 consecutive patients were included in this observational, single-center prospective study. The chemotherapy regimens were classified as having a low (<10%), intermediate (10–20%), or high (>20%) risk for inducing neutropenia. ResultsThe overall removal rate due to complications was 7.2%. Among them, port-related infection (2.5%) and port expulsion (1%) were the most frequent. The interval between port insertion and its first use was shown to be a predictive factor for complication-related removal rates. A cut-off of 6 days was statistically significant (p = 0.008), as the removal rate for complications was 9.4% when this interval was 0–5 days and 5.7% when it was ≥6 days. Another factor associated with port complication rate was the neutropenia-inducing potential of the chemotherapy regimens used, with removal for complications involved in 5.5% of low-risk regimens versus 9.4% for the intermediate- and high-risk regimens (p = 0.003). ConclusionAn interval of 6 days between placement and first use of the port reduces the removal rate from complications. The intermediate- and high-risk for neutropenia chemotherapy regimens are related to higher port removal rates from complications than low-risk regimens.

Continuous amnioinfusion via a subcutaneously implanted port system with PPROM and anhydramnios &lt; 28+0 weeks of gestation: an international prospective randomized trial

Continuous amnioinfusion via a subcutaneously implanted port system with PPROM and anhydramnios &lt; 28+0 weeks of gestation: an international prospective randomized trial

Response of severe IUGR human fetuses with brain sparing to amino acids supplementation via subcutaneously implanted port system with and without hyperbaric oxygenation

Objective: This study aims to treat severe placental insufficiency with amino acid and glucose intraumbilical supplementation via a port system and hyperbaric oxygenation (HBO).

Totally implantable venous access port systems and associated complications: A single-institution retrospective analysis of 2,996 breast cancer patients.

Totally implantable venous access port systems (TIVAPS) are widely used in breast cancer patients. However, complications are frequent and may necessitate device replacement or removal, resulting in additional patient stress and treatment delays. The aim of this study was to investigate possible risk factors for complications. A total of 2,996 consecutive female breast cancer patients, with a median age of 50.2 years (range, 21.2-85.5 years) were enrolled in this observational, single-centre study between December, 2008 and April, 2014. TIVAPS implantation was principally performed using local anaesthesia and the blind puncture or Seldinger technique through internal jugular or subclavian vein access. A retrospective chart review was conducted to obtain information associated with TIVAPS and patient data. Insertion performed by blind puncture and Seldinger technique had a success ratio of 96.34 and 99.80%, respectively (χ2=29.905, P<0.001). However, the success ratio of the puncture technique group was 99.76% when the TIVAPS was implanted in the right internal jugular vein. The most common complications were late complications, with an overall incidence rate of 5.41% (162/2,996) during the entire device duration. The most common late complications included fibrin formation (1.84%, 55/2,996), port-related bacteraemia (1.44%, 43/2,996) and deep vein thrombosis (0.63%, 19/2,996). No patient died during the study. Our results demonstrated that insertion of TIVAPS by blind puncture or the Seldinger technique through internal jugular or subclavian vein access is convenient, and insertion by the Seldinger technique through the right internal jugular vein is the preferred method. Therefore, TIVAPS is safe for continuous infusional chemotherapy regimens for breast cancer patients.

Catheter-Related Bloodstream Infections in Pediatric Oncology: Prevention and Treatment

Introduction. Prevention and treatment of catheter-related bloodstream infections (CRBI) are one of the priorities in the treatment of children with oncological diseases because the most common way of administration of chemotherapy drug administration is intravenous. Materials and methods. The analysis included 186 cancer patients aged from 2 months to 17 years (mean age 6.4 years) who were established implantable venous port systems (IVPs) with the aim of chemotherapy at the Institute of Pediatric Oncology and Hematology between 2010 and 2015. As IVPs lock solutions saline, saline solution with traces of heparin or Taurolock were used. In cases of the IVPs catheter thrombosis, the flush was performed using saline solution or specialized drug Taurolock U25 000containing 25 000 IU urokinase. Results. CRBI were reported in 10 (5.4%) patients, which required the removal of 1 (0.53%) IVPs; infections of chamber’s pocket — in 5 (2.7%) patients, which required the removal of 4 (2.1%) IVPs; IVPs occlusions due to blood clots — 52 cases in 43 (23.1%) patients. In 9 (90%) out of 10 cases, registered infectious complications were treated with Taurolock. In 2 (20%) cases, taurolidine administration was combined with the antibiotic therapy through the peripheral catheter. In 1 (10%), infection was treated only with antibiotic therapy through the peripheral catheter. In all cases of IVPs thrombosis, the patency was restored. Thus in 5 (9.6%) ou of 52 patients IVPs patency has been restored using saline flush solution, in 47 (90.4%) out of 52 — Taurolock U25000: in 45 (95.7%) patients IVPs patency was restored after the first administration of the drug, in 2 (4.3%) — after the second. Conclusion. Taurolock and Taurolock U25 000 showed their high effectiveness in the treatment of CRBI and catheter thrombosis, which allows us to recommend these drugs for wide administration in clinics dealing with the treatment of cancer patients.